Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Intervenn attracts $201m in series C
Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
T-Knife secures $110m in series B
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
Icosavax lands on $182m IPO
UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.
Tenaya tends to $180m IPO
The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.
Daily deal net: July 30, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Deep Genomics jumps into $180m series C
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.
IgGenix initiates $25m series A1
Co-founded by Stanford researchers, IgGenix is working on therapies that address severe allergies.
Tepha ticks acquisition box
Based on research originally conducted at MIT, Tepha has been purchased by BD for an undisclosed sum.

Other News

Ring circles $117m series B
UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.
Topas tops up series B
Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.
Embark passes series B test with $75m
Cornell-linked dog DNA test developer Embark Veterinary raised the capital in a round led by SoftBank Vision Fund 2 at a $700m post-money valuation.
Onera Health wakes up to $12.7m
Imec.xpand has returned to back a series B round for sleep diagnostic developer Onera Health, spun out of Imec.
Investors assist Artios in $153m series C
IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.
Sema4 secures Nasdaq listing
Icahn School of Medicine spinout Sema4 has completed a reverse merger with CM Life Sciences to begin trading on the Nasdaq Global Select Market.

Editor's Picks

Aerovate accesses public markets
Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg